Guidelines & evidence base
The guidelines and primary sources behind AllergyCalc: 176 distinct sources across 11 source families — AAAAI/ACAAI practice parameters, EAACI, WAO, GINA and…
AAAAI / ACAAI Joint Task Force practice parameters
The US practice parameters — anaphylaxis, drug allergy, rhinitis, atopic dermatitis, stinging insect, and inborn errors of immunity.
- Orange JS, Chinen J, Horner CC, et al. 2025 Inborn errors of immunity practice parameter (JTFPP/AAAAI/ACAAI/CIS). Ann Allergy Asthma Immunol. 2026;136(4):426-493.e1. — used by: Inborn errors of immunity: phenotype-driven screen, PPSV23 testable-serotype denominator (PCV-conjugate era), PPSV23 polysaccharide response interpretation, IEI screening by clinical phenotype
- Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124-176. — used by: Anaphylaxis: recognition & treatment, Allergen immunotherapy: candidacy, safety & duration
- AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 AAAAI/ACAAI Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312. — used by: Atopic dermatitis: stepwise management
- Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-398. — used by: CRSwNP & N-ERD (AERD) pathway
- Kim S, Marcus B, Monteiro R, et al. The chronic rhinosinusitis practice parameter. Ann Allergy Asthma Immunol. 2023;131(3):307-323. — used by: CRSwNP & N-ERD (AERD) pathway
- Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-1393. — used by: Penicillin / drug allergy delabeling pathway, NSAID Hypersensitivity Classification & Management, Drug Desensitization, Rapid Induction of Tolerance, Severe cutaneous adverse reaction (SCAR) pathway, Local anesthetic reaction, evaluation & delabeling, Drug reaction phenotypes & approach
- Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis, a 2020 practice parameter update. J Allergy Clin Immunol. 2020;145(4):1082-1123. — used by: Anaphylaxis: recognition & treatment, Idiopathic Anaphylaxis, Exclusion & Management, IM epinephrine dose for anaphylaxis (0.01 mg/kg)
- Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. — used by: Rhinitis classification & management, Ocular allergy, classify and treat by subtype
- Golden DBK, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28-54. — used by: Stinging insect allergy & venom immunotherapy
- Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.e78. — used by: Inborn errors of immunity: phenotype-driven screen, Antibody Deficiency, Humoral Immunodeficiency Workup, IEI screening by clinical phenotype
- Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter–update 2015. J Allergy Clin Immunol Pract. 2015;3(3 Suppl):S1-39. — used by: Contact Dermatitis, Allergic vs Irritant
- Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43. — used by: Vaccine allergy & reaction evaluation, Vaccine excipients & allergy relevance
- Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-S55. — used by: Allergen immunotherapy: candidacy, safety & duration
EAACI guidelines and position papers
European Academy of Allergy and Clinical Immunology — food allergy diagnosis, immunotherapy, urticaria, N-ERD, and venom allergy.
- Sampson HA, Arasi S, Bahnson HT, et al. AAAAI-EAACI PRACTALL: Standardizing oral food challenges, 2024 Update. Pediatr Allergy Immunol. 2024;35(11):e14276. — used by: Food allergy evaluation, OFC & prevention
- Riggioni C, Riggioni C, Comberiati P, et al. Immunotherapy and biologics in the management of IgE-mediated food allergy: systematic review and meta-analyses of efficacy and safety. Allergy. 2024;79(8):2097-2127. — used by: Food Oral Immunotherapy, Candidacy & Management
- Riggioni C, Ricci C, Moya B, et al. Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy. Allergy. 2024;79(2):324-352. — used by: Component-resolved diagnostics (CRD), how to read the result
- Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy. 2023;78(12):3057-3076. — used by: Food allergy evaluation, OFC & prevention, Component-resolved diagnostics (CRD), how to read the result
- Greenhawt M, Shaker M, Golden DBK, et al. Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: a systematic review and meta-analysis. Allergy. 2023;78(1):71-83. — used by: Vaccine allergy & reaction evaluation, Vaccine excipients & allergy relevance
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema, 2021 revision and update. Allergy. 2022;77(7):1961-1990. — used by: Angioedema differential & HAE pathway, Hereditary angioedema: attack treatment & prophylaxis, HAE Acute Attack, Emergency Management, HAE / angioedema complement profile interpreter, Histaminergic vs bradykinin-mediated angioedema, HAE long-term prophylaxis (LTP) & on-demand agent selection
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. — used by: Angioedema differential & HAE pathway, Chronic spontaneous urticaria (CSU) workup & ladder, Chronic Inducible Urticaria, Subtype & Management
- Weller K, Donoso T, Magerl M, et al. Development of the Angioedema Control Test, a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy. 2020;75(5):1165-1177. — used by: Angioedema Control Test (AECT)
- Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD), an EAACI position paper. Allergy. 2019;74(1):28-39. — used by: CRSwNP & N-ERD (AERD) pathway, NSAID Hypersensitivity Classification & Management
- Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018;73(4):744-764. — used by: Stinging insect allergy & venom immunotherapy, Allergen immunotherapy: candidacy, safety & duration
- Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73(4):799-815. — used by: Food Oral Immunotherapy, Candidacy & Management
- Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias, The EAACI/GA²LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802. — used by: Chronic Inducible Urticaria, Subtype & Management
- Vandenplas O, Wiszniewska M, Raulf M, et al. EAACI position paper: irritant-induced asthma. Allergy. 2014;69(9):1141-1153. — used by: Occupational Asthma, Diagnosis & Classification
- Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219-1232. — used by: NSAID Hypersensitivity Classification & Management
- Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-873. — used by: ABPA, Allergic Bronchopulmonary Aspergillosis
- Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777-780. — used by: Urticaria Activity Score over 7 days (UAS7)
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63(Suppl 86):8-160. — used by: ARIA allergic rhinitis classification
WAO guidance
World Allergy Organization — anaphylaxis guidance and the hereditary angioedema guideline.
- Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ J. 2020;13(10):100472. — used by: Anaphylaxis: recognition & treatment, IM epinephrine dose for anaphylaxis (0.01 mg/kg)
- Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37. — used by: Anaphylaxis: recognition & treatment
Respiratory: GINA, ATS/ERS, GOLD
Asthma strategy and lung-function interpretation standards, including the ATS/ERS 2022 change to bronchodilator responsiveness.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024/2025 reports (no SABA monotherapy; ICS-formoterol reliever). — used by: Asthma / PFT / EIB diagnostic & treatment pathway
- Agarwal R, Sehgal IS, Muthu V, et al. Revised clinical practice guidelines for diagnosing, classifying, and treating allergic bronchopulmonary aspergillosis/mycoses: an ISHAM-ABPA working group report. Eur Respir J. 2024;63(4):2400061. — used by: ABPA, Allergic Bronchopulmonary Aspergillosis
- Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. — used by: Asthma / PFT / EIB diagnostic & treatment pathway, Spirometry: FEV1/FVC & obstruction pattern
- Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. — used by: Severe asthma biologic selection, Atopic march biologic selection
- Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and MCAS. Int Arch Allergy Immunol. 2019;180(1):44-51. — used by: Acute tryptase "20% + 2" rule
- De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute eosinophilic pneumonia. Causes, diagnosis, and management. Am J Respir Crit Care Med. 2018;197(6):728-736. — used by: Eosinophilic Pneumonia, Acute vs Chronic
- Agarwal R, Aggarwal AN, Dhooria S, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47(2):490-498. — used by: ABPA, Allergic Bronchopulmonary Aspergillosis
- Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-1080. — used by: Severe cutaneous adverse reaction (SCAR) pathway, RegiSCAR DRESS validation score
- Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official ATS clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016-1027. — used by: Asthma / PFT / EIB diagnostic & treatment pathway
- Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J. 2012;39(3):529-545. — used by: Occupational Asthma, Diagnosis & Classification
- Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide (FeNO). Am J Respir Crit Care Med. 2011;184(5):602-615. — used by: Asthma / PFT / EIB diagnostic & treatment pathway, FeNO interpretation (ATS 2011)
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, fixed FEV1/FVC <0.70 obstruction criterion. — used by: Spirometry: FEV1/FVC & obstruction pattern
Gastroenterology: ACG and AGREE
Eosinophilic esophagitis — the AGREE consensus criteria and the ACG clinical guideline.
- Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59. — used by: EREFS, EoE endoscopic reference score, Eosinophilic GI disorder (EGID) biologic selection
- Dellon ES, Khoury P, Muir AB, et al. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology. 2022;163(1):59-76. — used by: I-SEE, Index of Severity for EoE
- Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122. — used by: Eosinophilic GI disorder (EGID) biologic selection
- Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis (AGREE). Gastroenterology. 2018;155(4):1022-1033. — used by: Eosinophilic esophagitis: diagnosis & treatment, Eosinophilic esophagitis histologic threshold, Eosinophilic GI disorder (EGID) biologic selection
- Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis (EREFS). Gut. 2013;62(4):489-495. — used by: Eosinophilic esophagitis: diagnosis & treatment, EREFS, EoE endoscopic reference score
Rheumatology: ACR / EULAR
Vasculitis classification and management, including the 2022 ACR/EULAR EGPA classification criteria.
- Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology / European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309-314. — used by: EGPA: diagnosis & treatment stratification
- Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2022;74(3):386-392. — used by: EGPA classification, 2022 ACR/EULAR criteria
- Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. — used by: EGPA: diagnosis & treatment stratification
Hematology: WHO / ICC classifications
Mast cell and eosinophilic neoplasm classification, including the WHO 5th edition and ICC 2022.
- Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946-968. — used by: Absolute eosinophil count & hypereosinophilia grading
- Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(7):1097-1116. — used by: Systemic Mastocytosis, Diagnosis & Subtyping, Mast cell disorders: diagnosis & management
- Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(1):129-148. — used by: Hypereosinophilic Syndrome, Workup & Variant-Directed Therapy
- Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646. — used by: Systemic Mastocytosis, Diagnosis & Subtyping, Systemic mastocytosis diagnostic criteria (WHO/ICC)
- Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736. — used by: Mast cell activation syndrome (MCAS) targeted therapy
- Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103(8):2879-2891. — used by: Hypereosinophilic Syndrome, Workup & Variant-Directed Therapy
FDA labels and approvals
Prescribing information and approval decisions — the authority for dose, route, age indication, and boxed warnings.
- US FDA approvals: dupilumab for H1-antihistamine-refractory CSU (Apr 2025); remibrutinib (oral BTK inhibitor) for CSU (Sep 2025). — used by: Chronic spontaneous urticaria (CSU) workup & ladder
- Tezepelumab (anti-TSLP) FDA approval for CRSwNP, Oct 2025 (WAYPOINT trial). — used by: CRSwNP & N-ERD (AERD) pathway
- EKTERLY (sebetralstat) US prescribing information. KalVista Pharmaceuticals; 2025. — used by: Hereditary angioedema: attack treatment & prophylaxis
- ANDEMBRY (garadacimab-gxii) US prescribing information. CSL Behring; 2025. — used by: Hereditary angioedema: attack treatment & prophylaxis
- DAWNZERA (donidalorsen) US prescribing information. Ionis Pharmaceuticals; 2025. — used by: Hereditary angioedema: attack treatment & prophylaxis
- FDA approval of neffy (epinephrine nasal spray), ARS Pharmaceuticals, 2 mg (Aug 2024) and 1 mg pediatric 15–<30 kg (Mar 2025). — used by: Intranasal epinephrine (neffy) dose by weight
- Dupilumab (Dupixent) FDA approval for EoE: May 2022 (≥12 yr, ≥40 kg), expanded Jan 2024 (ages 1-11, ≥15 kg). Budesonide oral suspension (Eohilia) FDA approval Feb 2024. — used by: Eosinophilic esophagitis: diagnosis & treatment
- Benralizumab (Fasenra) FDA approval for eosinophilic granulomatosis with polyangiitis in adults, 18 September 2024, 30 mg SC every 4 weeks; based on the phase 3 MANDARA trial. — used by: EGPA: diagnosis & treatment stratification
- ORLADEYO (berotralstat) US prescribing information. BioCryst Pharmaceuticals; 2024. — used by: Hereditary angioedema: attack treatment & prophylaxis
- AYVAKIT (avapritinib) US prescribing information. Blueprint Medicines; 2023. — used by: Mast cell disorders: diagnosis & management
- RYDAPT (midostaurin) US prescribing information. Novartis; 2017. — used by: Mast cell disorders: diagnosis & management
- Serotype compositions from FDA package inserts: Pneumovax 23 (PPSV23), Prevnar 13, Vaxneuvance (PCV15), Prevnar 20, Capvaxive (PCV21/V116). — used by: PPSV23 testable-serotype denominator (PCV-conjugate era)
CDC / ACIP
Immunization recommendations and vaccine-safety guidance, including pneumococcal vaccine policy.
- Vaccine Excipient Summary, Excipients Included in US Vaccines, by Vaccine. Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health; 2024 (mirror of CDC Pink Book Appendix B). — used by: Vaccine excipients & allergy relevance
- Thompson JM, Carpenter A, Kersh GJ, Wachs T, Commins SP, Salzer JS. Geographic distribution of suspected alpha-gal syndrome cases, United States, January 2017–December 2022. MMWR Morb Mortal Wkly Rep. 2023;72(30):815-820. — used by: Alpha-gal Syndrome, Diagnosis & Management
- Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP, United States, 2023-24 Influenza Season. MMWR Recomm Rep. 2023;72(2):1-25. — used by: Vaccine excipients & allergy relevance
Radiology: ACR contrast manual
Contrast-reaction prophylaxis — indications, regimens, and the evidence on breakthrough reactions.
- ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, 2024. Section: Patient Selection and Preparation Strategies (corticosteroid premedication, indications, and specific recommended regimens). — used by: Iodinated contrast reaction, premedication & re-exposure
- Mervak BM, Cohan RH, Ellis JH, et al. Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen. Radiology. 2017;285(2):425-433. — used by: Iodinated contrast reaction, premedication & re-exposure
- Davenport MS, Mervak BM, Ellis JH, et al. Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient Corticosteroid Prophylaxis before Contrast-enhanced CT. Radiology. 2016;279(2):492-501. — used by: Iodinated contrast reaction, premedication & re-exposure
- Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. AJR Am J Roentgenol. 2015;205(1):77-84. — used by: Iodinated contrast reaction, premedication & re-exposure
- Davenport MS, Cohan RH, Caoili EM, et al. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology. 2009;253(2):372-379. — used by: Iodinated contrast reaction, premedication & re-exposure
Primary studies and systematic reviews
Validation studies, randomised trials, and meta-analyses underpinning individual scores and thresholds.
- Bousfiha A, Moundir A, Tangye SG, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. 2025. — used by: Inborn errors of immunity: phenotype-driven screen
- Zuzolo J, Zulfiqar MF, Spoelhof B, et al. Functional testing of humoral immunity in the Prevnar 20 era. Ann Allergy Asthma Immunol. 2025;134(3):279-283. — used by: PPSV23 testable-serotype denominator (PCV-conjugate era)
- Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies (OUtMATCH). N Engl J Med. 2024;390(10):889-899. — used by: Food allergy evaluation, OFC & prevention
- Tariq F. Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends. Life (Basel). 2024;14(6):650. — used by: Ocular allergy, classify and treat by subtype
- Riedl MA, Aygören-Pürsün E, Bernstein JA, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks (KONFIDENT). N Engl J Med. 2024;391(1):32-43. — used by: HAE long-term prophylaxis (LTP) & on-demand agent selection
- Wise SK, Damask C, Roland LT, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis, 2023 (ICAR:AR-2023). — used by: Rhinitis classification & management
- Copaescu AM, Vogrin S, James F, et al. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Low-Risk Penicillin Allergy (PALACE). JAMA Intern Med. 2023;183(9):944-952. — used by: Penicillin / drug allergy delabeling pathway
- Kliewer KL, Gonsalves N, Dellon ES, et al. One-food versus six-food elimination diet therapy for eosinophilic oesophagitis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(5):408-421. — used by: Eosinophilic esophagitis: diagnosis & treatment
- Cottin V. Eosinophilic lung diseases. Immunol Allergy Clin North Am. 2023;43(2):289-322. — used by: Eosinophilic Pneumonia, Acute vs Chronic
- Jiang S, Tang M, et al. Allergy to Local Anesthetics is a Rarity: Review of Diagnostics and Strategies for Clinical Management. Clin Rev Allergy Immunol. 2023;64(2):193-205. — used by: Local anesthetic reaction, evaluation & delabeling
- Bruschi G, Ghiglioni DG, Cozzi L, et al. Vernal Keratoconjunctivitis: A Systematic Review. Clin Rev Allergy Immunol. 2023;65(2):277-329. — used by: Ocular allergy, classify and treat by subtype
- Bonnekoh H, Jelden-Thurm J, Butze M, et al. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time Course, Clinical Features, and Response to Treatment. J Allergy Clin Immunol Pract. 2023;11(9):2900-2910. — used by: Urticarial vasculitis, recognise, biopsy, stratify by complement
- Tanimoto S, Kaliner M, Lockey RF, et al. PK/PD comparison of epinephrine administered intranasally and intramuscularly. Ann Allergy Asthma Immunol. 2023;130(4):508-514.e1. — used by: Intranasal epinephrine (neffy) dose by weight
- Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317-2330. — used by: Atopic march biologic selection, Eosinophilic GI disorder (EGID) biologic selection
- Dellon ES, Khoury P, Muir AB, et al. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. J Allergy Clin Immunol. 2022;150(1):33-47. — used by: I-SEE, Index of Severity for EoE
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. — used by: Hereditary angioedema: attack treatment & prophylaxis, HAE Acute Attack, Emergency Management
- Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192-2199. — used by: Systemic Mastocytosis, Diagnosis & Subtyping, Mast cell activation syndrome (MCAS) targeted therapy
- Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis (ADVOCATE trial; enrolled GPA/MPA, not EGPA). N Engl J Med. 2021;384(7):599-609. — used by: EGPA: diagnosis & treatment stratification
- Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. — used by: Severe asthma biologic selection
- Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797-1810. — used by: Atopic march biologic selection
- Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164-172. — used by: HAE long-term prophylaxis (LTP) & on-demand agent selection
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. — used by: HAE long-term prophylaxis (LTP) & on-demand agent selection
- Trubiano JA, Vogrin S, Chua KYL, et al. Development and Validation of a Penicillin Allergy Clinical Decision Rule (PEN-FAST). JAMA Intern Med. 2020;180(5):745-752. — used by: Penicillin / drug allergy delabeling pathway, PEN-FAST penicillin allergy clinical decision rule
- Platts-Mills TAE, Commins SP, Biedermann T, van Hage M, Levin M, Beck LA, et al. On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Disease Workshop on understanding IgE-mediated mammalian meat allergy. J Allergy Clin Immunol. 2020;145(4):1061-1071. — used by: Alpha-gal Syndrome, Diagnosis & Management
- Commins SP. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clin Immunol. 2020;16(7):667-677. — used by: Alpha-gal Syndrome, Diagnosis & Management
- Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397-1405. — used by: Hypereosinophilic Syndrome, Workup & Variant-Directed Therapy
- Carter MC, Akin C, Castells MC, Scott EP, Lieberman P. Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice. Ann Allergy Asthma Immunol. 2020;124(1):16-27. — used by: Idiopathic Anaphylaxis, Exclusion & Management
- Perez EE. Diagnosis and management of specific antibody deficiency. Immunol Allergy Clin North Am. 2020;40(3):499-510. — used by: Antibody Deficiency, Humoral Immunodeficiency Workup
- Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test (AECT), a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract. 2020;8(6):2050-2057.e4. — used by: Angioedema Control Test (AECT)
- Garvey LH, Dewachter P, Hepner DL, et al. Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. Br J Anaesth. 2019;123(1):e50-e64. — used by: Perioperative Anaphylaxis, Management & Culprit Workup
- Suzuki Y, Suda T. Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413-419. — used by: Eosinophilic Pneumonia, Acute vs Chronic
- Kolkhir P, Grakhova M, Bonnekoh H, et al. Treatment of urticarial vasculitis: A systematic review. J Allergy Clin Immunol. 2019;143(2):458-466. — used by: Urticarial vasculitis, recognise, biopsy, stratify by complement
- Noe MH, Rosenbach M, Hubbard RA, et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With SJS/TEN (ABCD-10). JAMA Dermatol. 2019;155(4):448-454. — used by: ABCD-10 (SJS/TEN in-hospital mortality)
- Carlson G, Coop C. Pollen food allergy syndrome (PFAS): A review of current available literature. Ann Allergy Asthma Immunol. 2019;123(4):359-365. — used by: Pollen-food allergy syndrome cross-reactivity
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. — used by: Atopic march biologic selection
- Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133. — used by: Mast cell activation syndrome (MCAS) targeted therapy
- Zagursky RJ, Pichichero ME. Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81. — used by: Penicillin / drug allergy delabeling pathway, β-lactam side-chain cross-reactivity
- White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease. N Engl J Med. 2018;379(11):1060-1070. — used by: NSAID Hypersensitivity Classification & Management
- Harper NJN, Cook TM, Garcez T, et al. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaesth. 2018;121(1):159-171. — used by: Perioperative Anaphylaxis, Management & Culprit Workup
- Harper NJN, Cook TM, Garcez T, et al. Anaesthesia, surgery, and life-threatening allergic reactions: management and outcomes in the 6th National Audit Project (NAP6). Br J Anaesth. 2018;121(1):172-188. — used by: Perioperative Anaphylaxis, Management & Culprit Workup
- PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991-2001. — used by: Food Oral Immunotherapy, Candidacy & Management
- Romano A, Valluzzi RL, Caruso C, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract. 2018;6(5):1662-1672. — used by: β-lactam side-chain cross-reactivity
- Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity Score, validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1. — used by: Urticaria Activity Score over 7 days (UAS7)
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. — used by: Severe asthma biologic selection
- Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46. — used by: Antibody Deficiency, Humoral Immunodeficiency Workup, PPSV23 polysaccharide response interpretation
- Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States. J Allergy Clin Immunol. 2017;139(1):29-44. — used by: Food allergy evaluation, OFC & prevention
- Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011. — used by: Severe cutaneous adverse reaction (SCAR) pathway
- Wechsler ME, Akuthota P, Jayne D, et al. (MIRRA study). Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. — used by: EGPA: diagnosis & treatment stratification
- Nowak-Węgrzyn A, Chehade M, Groetch ME, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: Executive summary, Workgroup Report of the Adverse Reactions to Foods Committee, AAAAI. J Allergy Clin Immunol. 2017;139(4):1111-1126. — used by: FPIES, Food Protein-Induced Enterocolitis Syndrome
- Kelly KJ, Sussman G. Latex allergy: where are we now and how did we get there? J Allergy Clin Immunol Pract. 2017;5(5):1212-1216. — used by: Latex Allergy, Diagnosis & Management
- Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. — used by: HAE long-term prophylaxis (LTP) & on-demand agent selection
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. — used by: Atopic dermatitis: stepwise management
- Mowad CM, Anderson B, Scheinman P, et al. Allergic contact dermatitis: Patient management and education. J Am Acad Dermatol. 2016;74(6):1043-1054. — used by: Contact Dermatitis, Allergic vs Irritant
- Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541. — used by: Systemic Mastocytosis, Diagnosis & Subtyping
- Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38-59. — used by: Antibody Deficiency, Humoral Immunodeficiency Workup
- Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing, recommendations on best practice. Contact Dermatitis. 2015;73(4):195-221. — used by: Contact Dermatitis, Allergic vs Irritant
- Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75. — used by: Chronic Inducible Urticaria, Subtype & Management
- Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. — used by: Angioedema differential & HAE pathway, Chronic spontaneous urticaria (CSU) workup & ladder, Histaminergic vs bradykinin-mediated angioedema
- Caubet JC, Ford LS, Sickles L, et al. Clinical features and resolution of food protein-induced enterocolitis syndrome: 10-year experience. J Allergy Clin Immunol. 2014;134(2):382-389. — used by: FPIES, Food Protein-Induced Enterocolitis Syndrome
- Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med. 2014;370(7):640-649. — used by: Occupational Asthma, Diagnosis & Classification
- Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. Immunol Allergy Clin North Am. 2014;34(3):525-546. — used by: Perioperative Anaphylaxis, Management & Culprit Workup
- Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468-475. — used by: Food Oral Immunotherapy, Candidacy & Management
- Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test. J Allergy Clin Immunol. 2014;133(5):1365-1372, 1372.e1-6. — used by: Urticaria Control Test (UCT)
- Holbrook T, Keet CA, Frischmeyer-Guerrerio PA, Wood RA. Use of ondansetron for food protein-induced enterocolitis syndrome. J Allergy Clin Immunol. 2013;132(5):1219-1220. — used by: FPIES, Food Protein-Induced Enterocolitis Syndrome
- Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612. — used by: Hypereosinophilic Syndrome, Workup & Variant-Directed Therapy, Absolute eosinophil count & hypereosinophilia grading
- Cabañes N, Igea JM, de la Hoz B, et al. Latex allergy: Position paper. J Investig Allergol Clin Immunol. 2012;22(5):313-330. — used by: Latex Allergy, Diagnosis & Management
- Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the AAAAI. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-S24. — used by: Antibody Deficiency, Humoral Immunodeficiency Workup
- Bhole MV, Manson AL, Seneviratne SL, et al. IgE-mediated allergy to local anaesthetics: separating fact from perception: a UK perspective. Br J Anaesth. 2012;108(6):903-911. — used by: Local anesthetic reaction, evaluation & delabeling
- Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-225. — used by: Mast cell disorders: diagnosis & management
- Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders. Int Arch Allergy Immunol. 2012;157(3):215-225. — used by: Acute tryptase "20% + 2" rule
- Guillevin L, Pagnoux C, Seror R, et al. (French Vasculitis Study Group). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19-27. — used by: EGPA: diagnosis & treatment stratification, Five-Factor Score (FFS, 2011 revised)
- Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442-453. — used by: Perioperative Anaphylaxis, Management & Culprit Workup
- González-de-Olano D, Álvarez-Twose I, Esteban-López MI, et al. Venom immunotherapy in patients with mastocytosis and Hymenoptera venom anaphylaxis. Immunotherapy. 2011;3(5):641-654. — used by: Mast cell disorders: diagnosis & management
- Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-1104. — used by: Idiopathic Anaphylaxis, Exclusion & Management, Mast cell activation syndrome (MCAS) targeted therapy
- Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68. — used by: ALDEN, drug causality in SJS/TEN
- Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269-1278.e2. — used by: REMA score (clonal mast-cell disease prediction)
- Webber CM, England RW. Oral allergy syndrome: a clinical, diagnostic, and therapeutic challenge. Ann Allergy Asthma Immunol. 2010;104(2):101-108. — used by: Pollen-food allergy syndrome cross-reactivity
- Commins SP, Platts-Mills TAE. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol. 2009;124(4):652-657. — used by: Alpha-gal Syndrome, Diagnosis & Management
- Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454. — used by: Sino-Nasal Outcome Test (SNOT-22)
- Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-580. — used by: Drug Desensitization, Rapid Induction of Tolerance
- Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College of Chest Physicians Consensus Statement. Chest. 2008;134(3 Suppl):1S-41S. — used by: Occupational Asthma, Diagnosis & Classification
- Hopkins C, Browne JP, Slack R, et al. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg. 2007;137(4):555-561. — used by: Lund-Mackay sinus CT score
- Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. 2006;117(2):391-397. — used by: Anaphylaxis: recognition & treatment, Anaphylaxis clinical diagnostic criteria (NIAID/FAAN 2006)
- Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test. J Allergy Clin Immunol. 2004;113(1):59-65. — used by: Asthma Control Test (ACT)
- Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513-1519. — used by: Patient-Oriented Eczema Measure (POEM)
- Hepner DL, Castells MC. Latex allergy: an update. Anesth Analg. 2003;96(4):1219-1229. — used by: Latex Allergy, Diagnosis & Management
- Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-18. — used by: Eczema Area and Severity Index (EASI)
- Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153. — used by: Severe cutaneous adverse reaction (SCAR) pathway, SCORTEN, severity-of-illness score for SJS/TEN
- Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342(11):756-762. — used by: ABPA, Allergic Bronchopulmonary Aspergillosis
- Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. Medicine (Baltimore). 1998;77(5):299-312. — used by: Eosinophilic Pneumonia, Acute vs Chronic
- Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index. Dermatology. 1997;195(1):10-19. — used by: SCORAD (SCORing Atopic Dermatitis)
- Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology. 1993;31(4):183-184. — used by: Lund-Mackay sinus CT score
- European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report. Dermatology. 1993;186(1):23-31. — used by: SCORAD (SCORing Atopic Dermatitis)
- Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312(19):1229-1232. — used by: Drug Desensitization, Rapid Induction of Tolerance
- Schwartz HR, McDuffie FC, Black LF, et al. Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease. Mayo Clin Proc. 1982;57(4):231-238. — used by: Urticarial vasculitis, recognise, biopsy, stratify by complement
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. — used by: Naranjo Adverse Drug Reaction Probability Scale
- Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466-469. — used by: Ring & Messmer grading of anaphylaxis severity
- Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966;3(4):331-333. — used by: Mueller grading of systemic sting reactions
Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.